Literature DB >> 30709507

Complement and Transplantation: From New Mechanisms to Potential Biomarkers and Novel Treatment Strategies.

Julian K Horwitz1, Nicholas H Chun2, Peter S Heeger3.   

Abstract

The complement system, traditionally considered a component of innate immunity, is now recognized as a crucial mediator of the adaptive immune response in solid organ transplantation. Preclinical and early human trials have demonstrated the importance of complement effector mechanisms in driving allograft injury during specific antigraft immune responses, including ischemia-reperfusion injury, T-cell-mediated rejection, and antibody-mediated rejection, as well as a potential role for complement-derived risk stratification biomarkers. These data support the need for further testing of complement inhibitors in solid organ transplant recipients.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody-mediated rejection; Complement; Ischemia-reperfusion injury; T cells

Mesh：

Substances：

Year:  2018        PMID： 30709507      PMCID： PMC6361534          DOI： 10.1016/j.cll.2018.10.004

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN： 0272-2712            Impact factor:   1.935


  70 in total

1.  The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.

Authors:  J E Locke; C M Magro; A L Singer; D L Segev; M Haas; A T Hillel; K E King; E Kraus; L M Lees; J K Melancon; Z A Stewart; D S Warren; A A Zachary; R A Montgomery
Journal:  Am J Transplant       Date:  2008-10-31       Impact factor: 8.086

2.  Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction.

Authors:  Michael S Haas; Elisabeth M Alicot; Franziska Schuerpf; Isaac Chiu; Jinan Li; Francis D Moore; Michael C Carroll
Journal:  Cardiovasc Res       Date:  2010-05-11       Impact factor: 10.787

3.  Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation.

Authors:  Bart De Vries; Robert A Matthijsen; Tim G A M Wolfs; Annemarie A J H M Van Bijnen; Peter Heeringa; Wim A Buurman
Journal:  Transplantation       Date:  2003-02-15       Impact factor: 4.939

4.  Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.

Authors:  Peter N Lalli; Michael G Strainic; Min Yang; Feng Lin; M Edward Medof; Peter S Heeger
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

Review 5.  Natural IgM-mediated innate autoimmunity: a new target for early intervention of ischemia-reperfusion injury.

Authors:  Ming Zhang; Michael C Carroll
Journal:  Expert Opin Biol Ther       Date:  2007-10       Impact factor: 4.388

6.  Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells.

Authors:  William van der Touw; Paolo Cravedi; Wing-hong Kwan; Estela Paz-Artal; Miriam Merad; Peter S Heeger
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

Review 7.  Complement in immune and inflammatory disorders: pathophysiological mechanisms.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

8.  A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.

Authors:  Stanley C Jordan; Jua Choi; Olivier Aubert; Mark Haas; Alexandre Loupy; Edmund Huang; Alice Peng; Irene Kim; Sabrina Louie; Noriko Ammerman; Reiad Najjar; Dechu Puliyanda; Ashley Vo
Journal:  Am J Transplant       Date:  2018-05-14       Impact factor: 8.086

Review 9.  Complement and viral pathogenesis.

Authors:  Kristina A Stoermer; Thomas E Morrison
Journal:  Virology       Date:  2011-02-02       Impact factor: 3.616

10.  Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage.

Authors:  Hetal Patel; Richard A G Smith; Steven H Sacks; Wuding Zhou
Journal:  J Am Soc Nephrol       Date:  2006-03-01       Impact factor: 10.121
View more
  5 in total

1.  Iguratimod Attenuates Macrophage Polarization and Antibody-Mediated Rejection After Renal Transplant by Regulating KLF4.

Authors:  Zhou Hang; Jintao Wei; Ming Zheng; Zeping Gui; Hao Chen; Li Sun; Shuang Fei; Zhijian Han; Jun Tao; Zijie Wang; Ruoyun Tan; Min Gu
Journal:  Front Pharmacol       Date:  2022-05-09       Impact factor: 5.988

Review 2.  Sterile inflammation in thoracic transplantation.

Authors:  C Corbin Frye; Amit I Bery; Daniel Kreisel; Hrishikesh S Kulkarni
Journal:  Cell Mol Life Sci       Date:  2020-08-17       Impact factor: 9.261

Review 3.  More than a Pore: Nonlytic Antimicrobial Functions of Complement and Bacterial Strategies for Evasion.

Authors:  Elisabet Bjanes; Victor Nizet
Journal:  Microbiol Mol Biol Rev       Date:  2021-01-27       Impact factor: 11.056

Review 4.  High-risk Corneal Transplantation: Recent Developments and Future Possibilities.

Authors:  W John Armitage; Christine Goodchild; Matthew D Griffin; David J Gunn; Jesper Hjortdal; Paul Lohan; Conor C Murphy; Uwe Pleyer; Thomas Ritter; Derek M Tole; Bertrand Vabres
Journal:  Transplantation       Date:  2019-12       Impact factor: 4.939

5.  High-activity Classical and Alternative Complement Pathway Genotypes-Association With Donor-specific Antibody-triggered Injury and Renal Allograft Survival.

Authors:  Blanka Mező; Roman Reindl-Schwaighofer; Farsad Eskandary; Andreas Heinzel; Markus Wahrmann; Konstantin Doberer; Andreas Heilos; Gregor Bond; Johannes Kläger; Nicolas Kozakowski; Helmuth Haslacher; Rainer Oberbauer; Ondřej Viklický; Petra Hrubá; Philip F Halloran; Krisztina Rusai; Zoltán Prohászka; Georg A Böhmig
Journal:  Transplant Direct       Date:  2020-02-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.